2024 will be another big year for weight loss drugs, which soared in popularity despite hefty price tags, mixed insurance coverage and unpleasant side.
2024 will be another big year for weight loss drugs, which soared in popularity despite hefty price tags, mixed insurance coverage and unpleasant side effects.
There is likely a long way to go before the U.S. sees increased insurance coverage of obesity drugs, but Novo Nordisk’s new data is a meaningful start.